BiotechTube

PIM447 + Ruxolitinib + LEE011

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelofibrosis

Conditions

Myelofibrosis

Trial Timeline

May 21, 2015 → Nov 9, 2020

NCT ID
NCT02370706

About PIM447 + Ruxolitinib + LEE011

PIM447 + Ruxolitinib + LEE011 is a phase 1 stage product being developed by Novartis for Myelofibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02370706. Target conditions include Myelofibrosis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02370706Phase 1Completed

Competing Products

20 competing products in Myelofibrosis

See all competitors
ProductCompanyStageHype Score
Ruxolitinib + AbemaciclibEli LillyPhase 1
33
Nusivertib + Ruxolitinib + MomelotinibSumitomo PharmaPhase 1/2
41
Ruxolitinib + NavitoclaxAbbViePhase 2
52
ABBV-744 + Navitoclax + RuxolitinibAbbViePhase 1
33
Placebo for Navitoclax + Ruxolitinib + NavitoclaxAbbViePhase 3
77
Mivebresib + Navitoclax + RuxolitinibAbbViePhase 1
33
Navitoclax + VenetoclaxAbbViePre-clinical
23
Navitoclax + Ruxolitinib + Best Available Therapy (BAT)AbbViePhase 3
77
NS-018 + Best Available TherapyNippon ShinyakuPhase 2
52
AZD1480AstraZenecaPhase 1
33
BomedemstatMerckPhase 2
52
Peginterferon alfa-2aMerckPhase 2
52
BomedemstatMerckPhase 1/2
41
MBG453 + NIS793 + Spartalizumab + DecitabineNovartisPhase 1
33
LDE225 + INC424NovartisPhase 1/2
41
Imatinib mesylateNovartisPhase 2
52
Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793NovartisPhase 1/2
41
Ruxolitinib + Ruxolitinib PlaceboNovartisPhase 3
77
RuxolitinibNovartisPre-clinical
23
ruxolitinibNovartisPhase 2
52

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85